In this review:
CAVEAT: molecular patterns of response and outcome
PFS better with ibrutinib ±rituximab vs. bendamustine + rituximab in older CLL
Anti-CD19 CAR T-cells + ibrutinib for CLL
Luspatercept for anaemia in transfusion-dependent MDS with ring sideroblasts
Hydroxycarbamide for sickle cell anaemia in sub-Saharan Africa
Emapalumab for paediatric primary HLH
RIC sibling transplant vs. no transplant in intermediate–high risk AML
Anti-CD33 BITE antibody construct for relapsed/refractory AML
Fatigue in ITP is often not recognised by physicians
Ravulizumab vs. eculizumab in PNH under eculizumab treatment
Feasibility of time-limited venetoclaxrituximab in relapsed/refractory CLL
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy
Please login below to download this issue (PDF)